SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as a report surfaced regarding security flaws in a battlefield communication system, triggering a sharp sell-off despite the company's rebuttal and claims that the issues were resolved. The community is debating the severity and validity of the report, with some viewing it as a buying opportunity while others express concerns about the company's valuation. Discussions also involve the potential impact on government contracts and the trustworthiness of news sources.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid discussions around Novo Nordisk's potential entry into the telehealth space with an obesity pill, which could impact HIMS' market share, while others are pointing out that weightloss is only a small part of the business. The community is debating whether this news presents a buying opportunity or signals a concerning shift in the competitive landscape, especially since some are looking at the COO exit as a negative catalyst. Some traders are noting technical levels and expressing frustration with the stock's volatile price action and seeming sensitivity to news.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors discuss its potential U.S. expansion and speculate on a possible Nasdaq relisting, with community members pointing to strong fundamentals driving the stock. The company's growth in China, coupled with Starbucks' struggles, is fueling optimism, while others remain cautious due to past accounting issues and the stock's OTC status.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending as retail investors and traders discuss its impressive recent gains and potential for future growth within the quantum computing sector. Community members are weighing the possibility of a short squeeze against concerns of overvaluation and a potential offering, while some highlight a recent purchase order announcement. The stock's momentum is drawing attention, with debates swirling around its long-term prospects compared to others in the quantum computing space.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation ($ACHR) is trending amid high trading volume and anticipation surrounding potential catalysts, including upcoming airshows and FAA certification progress. The community is actively discussing the possibility of a short squeeze, as well as potential partnerships, with some drawing attention to Tesla's presence in a recent promotional video. Discussions also involve comparisons to sector peer Joby Aviation, with some traders anticipating $ACHR closing the market cap gap.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors debate its AI spending and monetization strategies, highlighted by a recent report on AI chatbots exploring ad revenue. Community chatter reflects concerns about its recent price action, with some viewing it as a buying opportunity while others express bearish sentiment. Broader discussions include Meta's competition in the AI and AR spaces, particularly around its smart glasses.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth (USAR) is trending due to speculation surrounding potential US government investment, fueled by the CEO's confirmation of White House discussions; the community is debating the significance of these talks and comparing USAR to other rare earth companies like MP Materials and LAC. Some investors are concerned about potential dilution from share unlocks and insider selling, while others remain optimistic about USAR's role in securing a domestic rare earth supply chain amid increasing geopolitical tensions.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is trending amid speculation of a potential buyout, with community members pointing to increased volume and options activity as possible indicators. Chatter suggests that a big tech company could be interested in acquiring the AI firm to bolster its own AI capabilities. Despite recent financial results and leadership changes, the stock is seeing increased interest.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

CLNN is trending as community members discuss the potential for accelerated approval of its ALS treatment following positive commentary from the FDA. Conversations revolve around the company's cash flow, potential offerings, and the possibility of a data leak driving the recent price movement. Some investors express excitement and relief, while others remain cautious due to past experiences and the need for further positive developments.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience is trending amid community discussion around a potential short squeeze and recent gains. Some traders cite the company's fundamentals, upcoming data readouts, and potential for a large upside. Others remain cautious, pointing to past trial failures and ongoing discussions about a possible offering.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -13.64% and +11.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline

Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investing.com’s stocks of the week

Investing.com -- Markets concluded the week with a notable shift in sentiment. After reaching record highs earlier, U.S. stocks closed lower on Friday, impacted by macroeconomic concerns.

RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data

Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.

Rhythm Pharmaceuticals received a wave of price target hikes on Wednesday after releasing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rhythm-pharma-experimental-drug-yields-weight-reduction-in-brain-damage-related-obesity/chFy2A1R5KT">encouraging Phase 2 results</a> for bivamelagon, its experimental oral treatment for hypothalamic obesity.LeerinkLeerink bumped its target to $102 from $88, keeping an 'Outperform' rating on the stock.&nbsp;The firm updated its estimates following the company's disclosure of Phase 2 data for bivamelagon, which it described as “close to a best-case scenario.”&nbsp;Leerink said investor feedback has been highly positive regarding efficacy, with minimal concerns on safety.NeedhamNeedham increased its price target to $95 from $72 and kept a 'Buy' rating.&nbsp;The firm raised its probability of success (PoS) for the bivamelagon program to 70% from 40% based on the Phase 2 results and lowered its discount rate in its discounted cash flow (DCF) model to 8% from 9.5% to reflect reduced overall risk.&nbsp;Needham added that, aside from some manageable exceptions, the tolerability profile for bivamelagon looks better than&nbsp;that of setmelanotide.Morgan Stanley&nbsp;Morgan Stanley lifted its price target to $95 from $80 and maintained an 'Overweight' rating.&nbsp;The firm noted that the Phase 2 data indicated BMI reductions above the 10% threshold, in the range of setmelanotide, with an improved profile.&nbsp;Morgan Stanley stated that this supports the advancement of bivamelagon into Phase 3 trials, which are expected in the first half of 2026.&nbsp;The firm also said early data confirm the potential for bivamelagon to expand or extend Rhythm’s opportunity in hypothalamic obesity.BofABofA raised its price target to $95 from $73 and kept a 'Buy' rating.&nbsp;The firm cited the positive topline results for bivamelagon and said the data suggest an efficacy profile similar to setmelanotide, but with more convenient once-daily oral dosing.StifelStifel raised its target to $123 from $94 and maintained a 'Buy' rating.&nbsp;The firm cited the Phase 2 data for bivamelagon and stated the treatment is now “derisked” on efficacy and “mostly derisked” on safety.&nbsp;Stifel said Rhythm now has an opportunity to extend the duration of its MC4R franchise beyond 2040.Wells FargoWells Fargo increased its price target to $129 from $91 and kept an 'Overweight' rating.&nbsp;The firm said the Phase 2 data are a “key inflection” for Rhythm’s MC4R franchise and that the stock should “trade up meaningfully.”&nbsp;Wells estimates the data adds approximately $35 per share in value and significantly increases the probability of success and durability for Rhythm’s MC4R franchise into the mid-2040s.On Stocktwits, retail sentiment for Rhythm was ‘extremely bullish’ amid ‘extremely high’ message volume.<a href="https://stocktwits.com/symbol/RYTM">Rhythm’s stock</a> has risen 48.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Analysts from Wells Fargo, Stifel, and others raised their targets on Rhythm Pharma (RYTM) following the release of strong BMI reduction data for bivamelagon/ Photo credit: Getty Images

Rhythm Pharma Gets Price-Target Bump Ups To $129 After Oral Obesity Drug Impresses In Phase 2; Retail Appetite Swells

Rhythm Pharmaceuticals received a wave of price target hikes on Wednesday after releasing encouraging Phase 2 results for bivamelagon, its experimental oral treatment for hypothalamic obesity.

Equity

Analysts from Wells Fargo, Stifel, and others raised their targets following the release of strong BMI reduction data for bivamelagon.

Rhythm Pharmaceuticals, Inc. (RYTM) on Wednesday announced that its drug Bivamelagon achieved statistically significant and clinically meaningful reductions in body mass index (BMI) in patients with acquired hypothalamic obesity in a mid-stage trial.<a href="https://stocktwits.com/symbol/RYTM">Rhythm’s shares</a> were trading 31% higher at the time of writing.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-oral-mc4r-agonist-bivamelagon">said</a> that Bivamelagon achieved as much as a 9.3% reduction from baseline in body mass index at 14 weeks of treatment. Patients also reported meaningful reduction in their ‘most’ hunger scores at 14 weeks on therapy as compared to placebo, the company said.CEO David Meeker said that the company is excited by the results, which suggest Bivamelagon has the potential to treat patients with acquired hypothalamic obesity. Rhythm in-licensed Bivamelagon from LG Chem, Ltd in January 2024.Acquired hypothalamic obesity is a rare form of obesity that occurs following damage to the hypothalamic region of the brain, which most frequently follows the growth or surgical removal of craniopharyngioma, astrocytoma, or other rare brain tumors.Patients experience accelerated weight gain, a reduction in energy expenditure, and hyperphagia (a chronic pathological condition characterized by insatiable hunger, impaired satiety, and persistent abnormal food-seeking behaviors), leading to severe obesity within six to 12 months following tumor resection or other injury.Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity. The company is also refining the formulation of Bivamelagon, potentially to improve tolerability ahead of initiating a late-stage trial, as one of the 28 patients in the mid-stage study discontinued therapy due to rectal bleeding.Rhythm estimates there are 5,000 to 10,000 people living with hypothalamic obesity in the U.S., 5,000 to 8,000 people living with hypothalamic obesity in Japan, and 3,500 to 10,000 people living with hypothalamic obesity in the E.U.On Stocktwits, retail sentiment around RYTM jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_09_at_11_39_04_AM_png_f718a4e952.webp" alt="RYTM's Sentiment Meter and Message Volume as of 11:39 a.m. ET on July 9, 2025 | Source: Stocktwits" width="623" height="67"><figcaption>RYTM's Sentiment Meter and Message Volume as of 11:39 a.m. ET on July 9, 2025 | Source: Stocktwits</figcaption></figure>RYTM stock is up by about 52% this year and by about 90% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/trump-slaps-30-tariff-on-iraq-says-its-less-than-what-is-needed/chFy2f8R5Kb">Trump Slaps 30% Tariff On Iraq, Says It’s ‘Less Than What Is Needed’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Rhythm Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity

Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity.

Shares of Rhythm Pharmaceuticals Inc. (RYTM) traded 14% higher on Monday noon after the company<a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-pivotal-phase-3-transcend-trial"> announced</a> positive results from a trial of setmelanotide therapy in the treatment of acquired hypothalamic obesity and subsequent price target upgrades.The biopharmaceutical company announced positive results from its phase 3 trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for treating acquired hypothalamic obesity.Acquired hypothalamic setmelanotide is a rare form of obesity resulting from damage to the hypothalamus, resulting in accelerated weight gain and insatiable hunger.The company estimates there are 5,000 to 10,000 people living with hypothalamic obesity in the U.S.The company said that it observed a statistically significant and highly clinically meaningful reduction in body mass index (BMI) with setmelanotide in both adult and pediatric patients as compared to those administered with a placebo.CEO David Meeker said that the company is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025.Bank of America subsequently upgraded the pharmaceutical company’s rating to ‘Buy’ from ‘Neutral’ while also hiking the price target to $63, up from $60.BofA opined that the company’s setmelanotide is "likely approvable" based on recent data provided by the company.The recent pullback in the shares offers "additional upside opportunity", the analyst told investors, according to TheFly.Wells Fargo also raised its price target on the company to $91 from $80 while keeping an “Overweight” rating on the shares.The firm, which believes that the shares should be trading higher on the trial data, said that the trial results are “solid” and near the bull case.Wells sees Rhythm trading to over $100 per share by the end of 2025.On Stocktwits, retail sentiment about RYTM jumped higher in the ‘extremely bullish’ territory while message volume rose from ‘high’ to ‘extremely high’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:1302/294;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_07_at_2_11_21_PM_png_23de55ab36.webp" alt="RYTM's Sentiment Meter and Message Volume as of 2:10 p.m. ET on April 7, 2025 | Source: Stocktwits" width="1302" height="294"><figcaption>RYTM's Sentiment Meter and Message Volume as of 2:10 p.m. ET on April 7, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/RYTM">RYTM shares</a> are down by over 11% this year but up by nearly 28% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-threatens-china-with-50-additional-tariffs/chf1CZ6Rb7r">Trump Threatens China With 50% Additional Tariffs If Xi Jinping’s Administration Fails To Lift Duties By Tuesday, Warns Termination Of Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Rhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More Bullish 

CEO David Meeker said the company is preparing to submit a supplemental New Drug Application to the FDA and a Type II variation request to the European Medicines Agency in the third quarter of 2025. 

Eli Lilly, Roku among others added to Wells Fargo's tactical ideas list

Investing.com -- Wells Fargo has released its Q2 2025 Tactical Ideas list on Tuesday, highlighting 10 stocks across nine subsectors that analysts believe could see significant catalysts in the coming quarter. 

A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 4 Analysts

Latest Ratings for RYTM
 DateFirmActionFromTo Mar 2022Canaccord GenuityMaintainsBuy Mar 2022NeedhamMaintainsBuy Feb 2022NeedhamMaintainsBuy
 View More Analyst Ratings for RYTM

 View the...

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Rhythm Pharmaceuticals Inc.

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

RYTM
Rhythm Pharmaceuticals Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RYTM News

RYTM Rhythm Pharmaceuticals Inc.